Last updated: 25 April 2024 at 6:20pm EST

Myla Lai-Goldman Net Worth




The estimated Net Worth of Goldman Myla Lai is at least $11.5 Million dollars as of 26 March 2008. Myla Lai owns over 3,400 units of West Pharmaceutical Services stock worth over $6,850,949 and over the last 19 years he sold WST stock worth over $4,364,473. In addition, he makes $300,206 as Independent Director at West Pharmaceutical Services.

Myla Goldman WST stock SEC Form 4 insiders trading

Myla has made over 26 trades of the West Pharmaceutical Services stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 3,400 units of WST stock worth $247,588 on 26 March 2008.

The largest trade he's ever made was exercising 49,719 units of West Pharmaceutical Services stock on 17 May 2006 worth over $2,164,268. On average, Myla trades about 4,499 units every 14 days since 2006. As of 26 March 2008 he still owns at least 22,659 units of West Pharmaceutical Services stock.

You can see the complete history of Myla Lai stock trades at the bottom of the page.





Myla Lai-Goldman biography

Dr. Myla P. Lai-Goldman M.D. serves as Independent Director of the Company. Dr. Lai-Goldman is the Executive Chair of GeneCentric Therapeutics, Inc.—a precision medicine company—where she previously served as CEO and President since June 2011. She is also managing partner of Personalized Science, LLC, a clinical diagnostic consulting company that she founded in 2008. Previously, Dr. Lai-Goldman was CEO and Chief Scientific Officer of CancerGuide Diagnostics, Inc. Before joining CancerGuide Diagnostics, she held various roles including Executive Vice President, Chief Medical Officer and Chief Scientific Officer—at Laboratory Corporation of America Holdings (LabCorp) and its predecessor company, Roche Biomedical Laboratories, Inc. Additionally, Dr. Lai-Goldman has been a venture partner at Hatteras Venture Partners since August 2011. Dr. Lai-Goldman is Board-certified in anatomic and clinical pathology.

What is the salary of Myla Goldman?

As the Independent Director of West Pharmaceutical Services, the total compensation of Myla Goldman at West Pharmaceutical Services is $300,206. There are 16 executives at West Pharmaceutical Services getting paid more, with Eric Green having the highest compensation of $6,533,690.



How old is Myla Goldman?

Myla Goldman is 62, he's been the Independent Director of West Pharmaceutical Services since 2014. There are 6 older and 20 younger executives at West Pharmaceutical Services. The oldest executive at West Pharmaceutical Services, Inc. is Patrick Zenner, 73, who is the Independent Chairman of the Board.

What's Myla Goldman's mailing address?

Goldman's mailing address filed with the SEC is 530 HERMAN O. WEST DRIVE, , EXTON, PA, 19341.

Insiders trading at West Pharmaceutical Services

Over the last 19 years, insiders at West Pharmaceutical Services have traded over $32,829,857 worth of West Pharmaceutical Services stock and bought 19,924 units worth $1,139,950 . The most active insiders traders include Robert F Friel, Paolo Pucci, and Douglas A Michels. On average, West Pharmaceutical Services executives and independent directors trade stock every 40 days with the average trade being worth of $4,786,805. The most recent stock trade was executed by Charles Witherspoon on 19 August 2024, trading 1,029 units of WST stock currently worth $308,700.



What does West Pharmaceutical Services do?

west works side-by-side with healthcare partners from concept to the patient, designing and manufacturing packaging and delivery systems that promote efficiency, reliability and safety. west leads the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched knowledge of relevant pharmaceutical product testing, development and packaging. west supports customers from sales, manufacturing, and research and development locations in north and south america, europe, asia and australia.



Complete history of Myla Lai stock trades at Labcorp and West Pharmaceutical Services

Insider
Trans.
Transaction
Total value
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $247,588
26 Mar 2008
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $831,366
26 Mar 2008
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $712,756
26 Mar 2008
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $124,224
3 Mar 2008
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $127,640
25 Feb 2008
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $128,381
20 Feb 2008
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $8,074
14 Feb 2008
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $433,702
14 Feb 2008
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $208,224
14 Feb 2008
Goldman Myla Lai
EVP and Chief Medical Officer
Option $655,200
12 Feb 2008
Goldman Myla Lai
EVP and Chief Medical Officer
Option $655,200
12 Feb 2008
Goldman Myla Lai
EVP and Chief Medical Officer
Option $655,200
12 Feb 2008
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $113,806
5 Feb 2007
Goldman Myla Lai
EVP and Chief Medical Officer
Option $478,900
12 Jul 2006
Goldman Myla Lai
EVP and Chief Medical Officer
Option $2,164,268
17 May 2006
Goldman Myla Lai
EVP and Chief Medical Officer
Option $29,644
18 Apr 2006
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $93,374
1 Mar 2006
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $125,426
21 Feb 2006
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $570,059
21 Feb 2006
Goldman Myla Lai
EVP and Chief Medical Officer
Option $410,928
21 Feb 2006
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $122,137
17 Feb 2006
Goldman Myla Lai
EVP and Chief Medical Officer
Option $655,200
17 Feb 2006
Goldman Myla Lai
EVP and Chief Medical Officer
Option $1,451,833
10 Jan 2006
Goldman Myla Lai
EVP and Chief Medical Officer
Sale $517,716
9 Jan 2006
Goldman Myla Lai
EVP and Chief Medical Officer
Option $172,506
6 Jan 2006
Goldman Myla Lai
EVP and Chief Medical Officer
Option $250,635
5 Jan 2006


West Pharmaceutical Services executives and stock owners

West Pharmaceutical Services executives and other stock owners filed with the SEC include: